Details

Autor(en) / Beteiligte

• Lev, Eli I.
• Kornowski, Ran
• Teplisky, Igal
• Hasdai, David
• Rechavia, Eldad
• Shor, Nurit
• Battler, Alexander
• Assali, Abid R.

Titel

The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction

Ist Teil von

• International journal of cardiovascular interventions, 2005, Vol.7 (1), p.41-45

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2005

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• The role of small molecules anti-glycoprotein (GP) IIb/IIIa pharmacotherapy during acute myocardial infarction (AMI) has not been established. The purpose of our study was to evaluate the clinical outcomes of patients sustaining AMI who underwent emergent percutaneous coronary intervention (PCI) and who were distinguished by the use of the anti-GP IIb/IIIa agent eptifibatide. We studied a consecutive group of 216 patients who underwent PCI for acute ST-elevation myocardial infarction and compared the outcomes of patients who received eptifibatide just prior and following the procedure (n = 167) to those who were not on anti GP IIb/IIIa inhibitors (n = 49). On average, patients treated using eptifibatide were younger and were more likely to be men, hypertensive, and smokers. The eptifibatide treated patients were less likely to have diabetes and renal failure and had worse angiographic characteristics. There were no significant differences between the groups in any of the clinical outcomes, including the composite endpoint (e.g. death, MI, repeat revascularization) and the rate of sub-acute stent thrombosis. Nonetheless, there was a non-significant trend towards lower 30 day mortality in the eptifibatide group (4.8% versus 12%, P = 0.09). We concluded that in our comparative study of periprocedural administration of eptifibatide during emergent AMI angioplasty, there was a non-significant trend towards better short-term survival among eptifibatide treated patients although the composite endpoint did not differ between patients distinguished by the use of anti GP IIb/IIIa small molecule pharmacotherapy.